跳至主要内容
临床试验/ISRCTN83081599
ISRCTN83081599已完成未知

Post-treatment PLATelet aggregation-guided therapy FOR ST-segment elevation Myocardial infarction: a randomized trial

Clinical Center of Serbia (Serbia)0 个研究点目标入组 632 人开始时间: 2012年5月22日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
632

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Patients with intermediate to high risk for 30-day Major Adverse Cardiac Events (MACE) (RISK-PCI score >3) undergoing primary PCI with stent implantation within 12 hours of the onset of symptoms
  • 2. Ability to comply with study protocol
  • 3. Negative test for pregnancy for women of childbearing potential before enrollment and agreement to use a reliable method of birth control during the study

排除标准

  • Pre-procedural:
  • 1. Any history of hemorrhagic stroke
  • 2. Ischemic stroke within 30 days of randomization
  • 3. Evidence of active abnormal bleeding within 3 months of randomization
  • 4. High risk for bleeding on long-term clopidogrel therapy
  • 5. Current therapy with coumadin anticoagulation
  • 6. Pregnancy or nursing
  • 7. Current enrollment in another investigational drug or device study
  • Procedural:
  • 1. Balloon angioplasty without stent placement
  • 2. Unsuccessful pPCI (post-procedural TIMI flow 0)
  • Post-procedural:
  • 1. Died within 24 hours after loading dose
  • 2. Active internal bleeding
  • 3. Hemoglobin < 10 g/dL or drop in hemoglobin by =3 g/dL
  • 4. Platelet count < 100 000 x 10-9/L.
  • 5. Thrombin Receptor Activating Peptide (TRAP) value <500 AU
  • 6. Indication for permanent anticoagulant therapy

研究者

发起方
Clinical Center of Serbia (Serbia)

相似试验

已完成
2 期
Treatment results of combined platelet-rich plasma and fat injection in patients with velopharyngeal insufficiencyVelopharyngeal insufficiency.Unspecified soft tissue disorder related to use, overuse and pressure
IRCT201306018435N5Vice chancellor for research, Tehran University of Medical Sciences and Health Services15
进行中(未招募)
1 期
A study designed to evaluate a modified Anti-Platelet Therapy (drugs that prevent blood platelets from clotting) after implantation of a Firehawk drug-eluting stent (metallic tube, which is covered with a drug and inserted into stenosed blood vessels of the heart in order to keep them open) in patients who have experienced a heart attack and were treated with complete revascularisatio
EUCTR2020-005933-34-NLSorin CRM SAS (Microport CRM)2,246
进行中(未招募)
1 期
A study designed to evaluate a modified Anti-Platelet Therapy (drugs that prevent blood platelets from clotting) after implantation of a Firehawk drug-eluting stent (metallic tube, which is covered with a drug and inserted into stenosed blood vessels of the heart in order to keep them open) in patients who have experienced a heart attack and were treated with complete revascularisation (the lesion related to the heart attack and all other significant lesions were treated)
EUCTR2020-005933-34-ESSorin CRM SAS (Microport CRM)2,246
进行中(未招募)
1 期
A study designed to evaluate a modified Anti-Platelet Therapy (drugs that prevent blood platelets from clotting) after implantation of a Firehawk drug-eluting stent (metallic tube, which is covered with a drug and inserted into stenosed blood vessels of the heart in order to keep them open) in patients who have experienced a heart attack and were treated with complete revascularisation (the lesion related to the heart attack and all other significant lesions were treated)Patients with clinically stable, low to moderate complexity acute Myocardial Infarction (MItroponine-positive Non-ST-Elevation MI or ST-Elevation MI) requiring primary Percutaneous Coronary Intervention. Subjects will be enrolled after having undergone successful complete revascularization with the study stent (Firehawk). Shortened DAPT of 1 month followed by 11 months P2Y12-Inhibitor only is compared to the current guideline-recommended 12-months DAPT.MedDRA version: 20.0Level: SOCClassification code 10007541Term: Cardiac disordersSystem Organ Class: 10007541 - Cardiac disorders
EUCTR2020-005933-34-ATSorin CRM SAS (Microport CRM)2,246
进行中(未招募)
不适用
ACUTE-PRAS
JPRN-jRCTs031220079Fujimoto Shigeru200